Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RuoLan Qian

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Optics Express|October 20, 2023
Bidynamical all-optical reservoir computing for parallel task processingNian Fang, RuoLan Qian, Shuai Wang
International Journal of Cancer|January 8, 2019
Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysisLilan Yi, Junsheng Fan, Ruolan Qian, et al.
Drug Design, Development and Therapy|December 15, 2017
The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancerWenjie Guo, Sihan Liu, Xiaoli Zhang, et al.
Medicine|February 15, 2019
The efficacy of the new medical internship management network systemOudong Xia, Jiaqi Ye, Anqi Lin, et al.
Oncotargets and Therapy|March 15, 2018
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysisJunsheng Fan, Zengfei Xia, Xiaoli Zhang, et al.
Aging|August 15, 2022
Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancerHaigang Geng, Ruolan Qian, Linmeng Zhang, et al.
European Journal of Pharmacology|February 13, 2007
Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cellsHua Jiang, ChunHui Hou, ShuBing Zhang, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 24, 2025
PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinomaRuolan Qian, Yuchen Guo, Xiaolin Hu, et al.
Cancer Gene Therapy|December 1, 2023
Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancerHaigang Geng, Ruolan Qian, Yiqing Zhong, et al.
Theranostics|September 15, 2021
Mapping the landscape of synthetic lethal interactions in liver cancerChen Yang, Yuchen Guo, Ruolan Qian, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Optics Express|October 20, 2023
Bidynamical all-optical reservoir computing for parallel task processingNian Fang, RuoLan Qian, Shuai Wang
International Journal of Cancer|January 8, 2019
Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysisLilan Yi, Junsheng Fan, Ruolan Qian, et al.
Drug Design, Development and Therapy|December 15, 2017
The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancerWenjie Guo, Sihan Liu, Xiaoli Zhang, et al.
Medicine|February 15, 2019
The efficacy of the new medical internship management network systemOudong Xia, Jiaqi Ye, Anqi Lin, et al.
Oncotargets and Therapy|March 15, 2018
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysisJunsheng Fan, Zengfei Xia, Xiaoli Zhang, et al.
Aging|August 15, 2022
Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancerHaigang Geng, Ruolan Qian, Linmeng Zhang, et al.
European Journal of Pharmacology|February 13, 2007
Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cellsHua Jiang, ChunHui Hou, ShuBing Zhang, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 24, 2025
PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinomaRuolan Qian, Yuchen Guo, Xiaolin Hu, et al.
Cancer Gene Therapy|December 1, 2023
Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancerHaigang Geng, Ruolan Qian, Yiqing Zhong, et al.
Theranostics|September 15, 2021
Mapping the landscape of synthetic lethal interactions in liver cancerChen Yang, Yuchen Guo, Ruolan Qian, et al.
Pageof 2